HLB Wins First FDA Approval: Bile Duct Cancer Drug Ripictu, Not Its Liver Cancer Bet (KOSDAQ: 028300)

· Biotech · FDA · HLB · Korea Brief

Korea Supply Chain Brief · September 27, 2026

HLB (KOSDAQ: 028300) says its U.S. subsidiary won FDA approval for Ripictu, a targeted drug for bile duct cancer. It is the first time a Korean company filed a cancer drug application with the FDA itself and got it approved. But the drug is not the liver cancer therapy HLB has chased since 2007, and it was not invented in Korea. Here is how the pieces fit together.

CompanyRoleEvidence
HLB
KOSDAQ: 028300
Parent company of Elevar TherapeuticsAnnounced (company statement, reported by JoongAng Ilbo, Sep 27, 2026)
Elevar Therapeutics
(HLB's U.S. subsidiary, unlisted)
Filed the new drug application and handled the FDA review; will sell the drug in the U.S.Announced
Relay Therapeutics
NASDAQ: RLAY
Original developer of the compound (RLY-4008); licensed global rights to Elevar in December 2024Reported (JoongAng Ilbo)

What was approved

  • Drug: Ripictu (lirafugratinib), a targeted therapy that blocks FGFR2, a growth-signal receptor.
  • Patients: adults with advanced bile duct cancer (cholangiocarcinoma) carrying an FGFR2 gene alteration, after earlier treatment (second line).
  • Trial result reported: tumors shrank or disappeared in 46% of patients, and the response lasted a median of 11.8 months.
  • Launch: Elevar plans a U.S. launch in the fourth quarter of 2026 and wants to expand into other FGFR2-altered solid tumors.

Anatomy of the deal: in-licensed, not home-grown

The usual Korean biotech playbook is the reverse: develop a drug at home, then license it out to a global pharma company that runs the U.S. approval. Yuhan's lung cancer drug Lazertinib (Lazcluze in the U.S.) followed that path; Janssen held the global rights and handled the FDA filing.

HLB went the other way. Elevar bought worldwide rights to a U.S. biotech's clinical-stage drug in a deal worth up to US$500 million (about KRW 680 billion), then did the data analysis, filing and FDA negotiations itself. That is why the approval counts as a Korean company's own FDA filing, even though the molecule came from Relay.

StepWho
Discovered and early development (RLY-4008)Relay Therapeutics (U.S.)
Global rights acquired (Dec 2024, up to US$500M)Elevar Therapeutics (HLB)
FDA filing and reviewElevar Therapeutics (HLB)
U.S. sales (planned Q4 2026)Elevar Therapeutics (HLB)

What is still pending

HLB's long-running liver cancer program, rivoceranib combined with Jiangsu Hengrui's camrelizumab, has not been approved. According to the report, it has received three complete response letters (CRLs) from the FDA since 2024, and in July a problem arose at Hengrui's manufacturing site for rivoceranib's active ingredient. HLB says a later FDA inspection classified the site as "voluntary action indicated," meaning the main issues were resolved, and it plans to refile. Investors following HLB should treat the two programs separately: Ripictu is approved; the liver cancer combination is not.

Competition

Fierce Pharma, cited in the report, expects Ripictu to compete with existing FGFR inhibitors such as Incyte's Pemazyre and Taiho Oncology's Lytgobi. Ripictu is designed to hit FGFR2 selectively, with less effect on related proteins.

Quick FAQ

Did HLB's liver cancer drug get FDA approval?
No. The approval is for Ripictu, a bile duct cancer drug. The liver cancer combination (rivoceranib + camrelizumab) is still unapproved; HLB plans to refile.

Did HLB invent Ripictu?
No. It was developed by Relay Therapeutics as RLY-4008. HLB's subsidiary Elevar acquired the global rights in 2024 and took it through FDA approval.

When will it be sold?
Elevar plans a U.S. launch in the fourth quarter of 2026.

Source (Korean): JoongAng Ilbo (중앙일보), Sep 27, 2026, reporter Choi Eun-kyung. https://www.joongang.co.kr/article/25464939
This brief is our own summary and analysis of the report, not a translation. It is not investment advice. See our Disclaimer and evidence labels.
Stock Anatomy · Last checked: September 27, 2026

Related